2. Search Result
Search Result
Results for "

CIN

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

2

Peptides

1

Recombinant Proteins

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132809
    Baxdrostat

    CIN-107

    		 Mineralocorticoid Receptor Endocrinology
    Baxdrostat is a aldosterone synthase inhibitor .
    Baxdrostat
  • HY-132809A
    (S)-Baxdrostat

    (S)-CIN-107

    		 Mineralocorticoid Receptor Endocrinology
    (S)-Baxdrostat is the S-enantiomer of Baxdrostat. Baxdrostat is an aldosterone synthase inhibitor .
    (S)-Baxdrostat
  • HY-132809B
    (Rac)-Baxdrostat

    (Rac)-CIN-107

    		 Drug Isomer Endocrinology
    (Rac)-Baxdrostat is the isomer of Baxdrostat (HY-132809), and can be used as an experimental control. Baxdrostat is a aldosterone synthase inhibitor .
    (Rac)-Baxdrostat
  • HY-146584
    Cathepsin C-IN-5

    		Cathepsin Inflammation/Immunology
    Cathepsin C-IN-5 (compound SF38) is a potent, selective and orally active Cathepsin C inhibitor with IC50s of 59.9 nM, 4.26 µM, >5 µM, >5 µM, >5 µM for Cat C, Cat L, Cat S, Cat B, Cat K, respectively. Cathepsin C-IN-5 inhibits the Cat C activity in bone marrow and blood. Cathepsin C-IN-5 decreases the activation of NSPs (neutrophil serine proteases). Cathepsin C-IN-5 shows anti-inflammatory activity .
    Cathepsin C-IN-5
  • HY-163476
    PIP5K1C-IN-1

    		PI4P5K Inflammation/Immunology Cancer
    PIP5K1C-IN-1 (Compound 30) is a potent PIP5K1C inhibitor, with an IC50 of 0.80 nM. PIP5K1C-IN-1 exhibits low total clearance in mice and high levels of kinase selectivity. PIP5K1C-IN-1 can be used for the research of cancer and chronic pain .
    PIP5K1C-IN-1
  • HY-18606
    K-Ras G12C-IN-3

    		Ras Cancer
    K-Ras G12C-IN-3 (Compound VI-5) is an irreversible small molecule inhibitor of mutant K-Ras G12C. K-Ras G12C-IN-3 can be used in the research of cancers .
    K-Ras G12C-IN-3
  • HY-149602
    Glutaminase C-IN-2

    		Glutaminase Reactive Oxygen Species (ROS) Cancer
    Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC50 of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects .
    Glutaminase C-IN-2
  • HY-RS10298
    PDXP Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PDXP Human Pre-designed siRNA Set A contains three designed siRNAs for PDXP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PDXP Human Pre-designed siRNA Set A
    PDXP Human Pre-designed siRNA Set A
  • HY-146581
    Cathepsin C-IN-4

    		Cathepsin Inflammation/Immunology
    Cathepsin C-IN-4 (compound SF27) is a potent Cathepsin C (Cat C) inhibitor, with an IC50 of 65.6 nM. Cathepsin C-IN-4 also inhibits THP-1 and U937 cell, with IC50 values of 203.4 and 177.6 nM, respectively .
    Cathepsin C-IN-4
  • HY-146580
    Cathepsin C-IN-3

    		Cathepsin Inflammation/Immunology
    Cathepsin C-IN-3 (compound SF11) is a potent Cathepsin C (Cat C) inhibitor, with an IC50 of 61.79 nM. Cathepsin C-IN-3 also inhibits THP-1 and U937 cell, with IC50 values of 101.5 and 86.5 nM, respectively .
    Cathepsin C-IN-3
  • HY-108420
    INK4C-IN-2
    1 Publications Verification

    		 CDK Cancer
    INK4C-IN-2 (Compound 40) is the inhibitor for INK4C (also known as p18) and the activator for CDK4/6. INK4C-IN-2 increases the number and expansion capacity of mouse and human hematopoietic stem cells (HSCs) with EC50 of 5.21 nM, promotes the self-renewal and multilineage differentiation of HSCs. INK4C-IN-2 improves the expansion and long-term hematopoietic reconstruction ability of HSCs in mouse bone marrow transplantation model .
    INK4C-IN-2
  • HY-173522
    KIF2C-IN-1

    		Kinesin Cancer
    KIF2C-IN-1 (Compound 7S9) is a selective and potent small-molecule KIF2C inhibitor. KIF2C-IN-1 stabilizes the KIF2C-tubulin interaction, blocking the depolymerization of polyglutamylated microtubules. KIF2C-IN-1 enhances the cytotoxicity of Paclitaxel (HY-B0015) in paclitaxel-resistant triple-negative breast cancer (TNBC) cells and significantly reduces tumor growth combined with Paclitaxel in mouse models .
    KIF2C-IN-1
  • HY-174851
    KRAS G12C-IN-70

    		Ras Cancer
    KRAS G12C-IN-70 is a selective KRAS G12C mutant inhibitor. KRAS G12C-IN-70 blocks KRAS G12C-mediated downstream signaling pathways (e.g., RAF-MEK-ERK) and inhibits tumor cell proliferation. KRAS G12C-IN-70 is promising for research of KRAS G12C mutation-related tumors (such as non-small cell lung cancer, colorectal cancer) .
    KRAS G12C-IN-70
  • HY-146148
    KDM4C-IN-1
    2 Publications Verification

    		 Histone Demethylase Cancer
    KDM4C-IN-1 (Compound 4d) is a potent KDM4C inhibitor with an IC50 of 8 nM. KDM4C-IN-1 inhibits the growth of HepG2 and A549 cells with IC50s of 0.8 µM and 1.1 µM, respectively .
    KDM4C-IN-1
  • HY-155611
    Cathepsin C-IN-6

    		Cathepsin Inflammation/Immunology
    Cathepsin C-IN-6 (compound 2) is a E-64c-hydrazideas based inhibitor of cathepsin C with anti-inflammatory activity. Cathepsin C-IN-6 inhibts activation of neutrophil elastase，exhibits potential efficacy in inflammatory diseases with high neutrophil load (e.g.，chronic obstructive pulmonary disease) .
    Cathepsin C-IN-6
  • HY-103046
    UbcH5c-IN-1

    		E1/E2/E3 Enzyme Inflammation/Immunology
    UbcH5c-IN-1 (compound 6d) is a potent and selective small-molecule inhibitor of Ubiquitin-conjugating enzyme UbcH5c, with a Kd of 283 nM for E2 UbcH5c-IN-1 by covalent binding with Cys85. A promising lead compound for the development of new antirheumatoid arthritis (RA) agent .
    UbcH5c-IN-1
  • HY-162275
    JMJD1C-IN-1

    		Histone Demethylase Histone Methyltransferase STAT Cancer
    JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
    JMJD1C-IN-1
  • HY-18605
    K-Ras G12C-IN-2

    		Ras Cancer
    K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.
    K-Ras G12C-IN-2
  • HY-128771
    K-Ras G12C-IN-4

    		Ras Cancer
    K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS G12C .
    K-Ras G12C-IN-4
  • HY-12682
    Glutaminase C-IN-1
    Maximum Cited Publications
    7 Publications Verification

    Compound 968

    		 Glutaminase Cancer
    Glutaminase C-IN-1 (Compound 968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts .
    Glutaminase C-IN-1
  • HY-P2004
    FFAGLDD

    		MMP Cancer
    FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .
    FFAGLDD
  • HY-P2004A
    FFAGLDD TFA

    		MMP Cancer
    FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .
    FFAGLDD TFA
  • HY-18604
    K-Ras G12C-IN-1

    		Ras Cancer
    K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.
    K-Ras G12C-IN-1
  • HY-163477
    PIP5K1C-IN-2

    		PI4P5K Cancer
    PIP5K1C-IN-2 (compound 33) is a potent and selective 4-phosphate 5-kinases 1 C (PIP5K1C) inhibitor with an IC50 value of 0.0059 µM .
    PIP5K1C-IN-2
  • HY-179210
    ATX020

    		Kinesin Cancer
    ATX020 is a potent, selective and orally active kinesin KIF18A inhibitor. ATX020 inhibits the ATPase activity of KIF18A in humans, rats and dogs, with IC50 values of 0.11 μM, 0.16 μM and 0.24 μM, respectively. ATX020 shows high selectivity for other motor proteins (CENP-E, Eg5, KIF15, etc.), with IC50 values >10 μM and only has a weak inhibitory effect on KIF19 (IC50 = 6.1 μM). ATX020 can inhibit cancer cells proliferation .
    ATX020
  • HY-153066
    VLS-1272

    KIF18A-IN-7

    		 Kinesin Microtubule/Tubulin Apoptosis Cancer
    VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CIN High tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research .
    VLS-1272

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: